Suppression of joint destruction with subcutaneous tocilizumab for Japanese patients with rheumatoid arthritis in clinical practice

Yasuharu Nakashima, Masakazu Kondo, Eisuke Shono, Takashi Ishinishi, Hiroshi Tsukamoto, Koji Kuroda, Akira Maeyama, Hiroshi Harada, Masayuki Maekawa, Takashi Shimauchi, Ryuji Nagamine, Hiroshi Jojima, Seiji Yoshizawa, Tomomi Tsuru, Takeshi Otsuka, Hisaaki Miyahara, Eiichi Suematsu, Ken Wada, Shigeru Yoshizawa, Yasushi InoueTakaaki Fukuda, Satoshi Ikemura, Akihisa Haraguchi

研究成果: Contribution to journalArticle査読

抄録

Objectives: To investigate the efficacy of suppressing joint destruction with subcutaneous tocilizumab (TCZ-SC) for Japanese rheumatoid arthritis (RA) patients in the real-world clinical setting. Methods: This 1-year prospective, multicenter study included 110 RA patients in whom TCZ-SC was newly initiated. Primary endpoint was the change from baseline in vdH-modified total Sharp score (mTSS) at week 52. Structural remission was defined as yearly mTSS of 0.5 or less. Disease activity was evaluated using the disease activity score (DAS28-ESR) and clinical disease activity index (CDAI). Results: At baseline, the patients’ mean age was 58.6 years, and the mean disease duration was 10.6 years. The proportion of patients who were naïve for biologics was 44.5%, and 64.5% concomitantly received methotrexate. The yearly mTSS showed significant improvement from 9.41 before TCZ-SC initiation to −0.15 after 52 weeks. The structural remission rate was 76.1%. After 52 weeks, the DAS28-ESR and CDAI remission rates were 52% and 21%, respectively. Although the previous usage of biologics and baseline disease activity significantly affected the clinical remission, no factors with significant effects on structural remission were identified. Conclusion: These findings support the efficacy of TCZ-SC in suppressing disease activity as well as joint destruction over a 1-year period.

本文言語英語
ページ(範囲)807-815
ページ数9
ジャーナルModern Rheumatology
30
5
DOI
出版ステータス出版済み - 9 2 2020

All Science Journal Classification (ASJC) codes

  • Rheumatology

フィンガープリント 「Suppression of joint destruction with subcutaneous tocilizumab for Japanese patients with rheumatoid arthritis in clinical practice」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル